Global Neurofibromatosis Treatment Drugs Market
Global Neurofibromatosis Treatment Drugs Market

Neurofibromatosis Treatment Drugs Comprehensive Study by Type (Selumetinib, Bevacizumab, Koselugo), Application (Clinic, Hospital, Home Care), Distribution Channel (Online, Offline), Neurofibromas (Cutaneous, Subcutaneous, Plexiform) Players and Region - Global Market Outlook to 2025

Neurofibromatosis Treatment Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 238 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Neurofibromatosis Treatment Drugs Market?

Neurofibromatosis is a hereditarily acquired issue wherein the nerve tissue develops tumors. Neurofibromatosis-1 is an acquired issue wherein nerve tissue tumors (neurofibromas) structure in the skin, base layer of skin (subcutaneous tissue), and nerves from the mind (cranial nerves) and spinal rope (spinal root nerves). Neurofibromatosis 2 (NF2) is a hereditary issue wherein tumors structure on the nerves of the mind and spine (the focal sensory system).

The market study is being classified by Type (selumetinib, bevacizumab and koselugo), by Application (Clinic, Hospital and Home Care) and major geographies with country level break-up.

Arno Therapeutics Inc (United States), AstraZeneca Plc (United Kingdom), Beta Pharma Inc(United States), Lixte Biotechnology Holdings Inc (United States), Plex Pharmaceuticals Inc (United States), Recursion Pharmaceuticals Inc (United States), Genentech (United States), Amgen(United States) and Allergan(Ireland) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Neurofibromatosis Treatment Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Neurofibromatosis Treatment Drugs market by Type, Application and Region.

On the basis of geography, the market of Neurofibromatosis Treatment Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Commercial tie-ups and acquisitions by key players
  • Strong product pipeline, approval of new pediatric drugs, and outsourcing for drug development activities


Restraints
  • Adverse effect of the drug

Opportunities
  • Innovation in clinical research

Challenges
  • Difficulty in conducting clinical trials for the pediatric population


The U.S. Food and Drug Administration (FDA) has endorsed Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a typical sign in the illness neurofibromatosis type one (NF1). The FDA's endorsement of AstraZeneca's and MSD (Merck's) accommodation is a significant achievement for patients living with neurofibromatosis (NF), a hereditary problem that makes tumors develop on nerves all through the body. Influencing 1 of every 3,000 individuals of all populaces similarly, this declaration is the principal ever endorsed treatment for NF, and forecasts the potential for the improvement of treatment choices for all NF patients.
" FDA on June 28, 2019, to discuss a proposed NDA for the treatment of pediatric patients age 3 years and above, with neurofibromatosis type 1 symptomatic and/or progressive, inoperable plexiform neurofibroma based on the results of Study 11-C-0161, ďA Phase I/II Study of the Mitogen-Activated Protein Kinase (MEK)1 Inhibitor Selumetinib in Children with Neurofibromatosis Type I and Inoperable Plexiform Neurofibromas (SPRINT)"

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Neurofibromatosis Treatment Drugs Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • selumetinib
  • bevacizumab
  • koselugo
By Application
  • Clinic
  • Hospital
  • Home Care
By Distribution Channel
  • Online
  • Offline

By Neurofibromas
  • Cutaneous
  • Subcutaneous
  • Plexiform

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Commercial tie-ups and acquisitions by key players
      • 3.2.2. Strong product pipeline, approval of new pediatric drugs, and outsourcing for drug development activities
    • 3.3. Market Challenges
      • 3.3.1. Difficulty in conducting clinical trials for the pediatric population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurofibromatosis Treatment Drugs, by Type, Application, Distribution Channel, Neurofibromas and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Neurofibromatosis Treatment Drugs (Value)
      • 5.2.1. Global Neurofibromatosis Treatment Drugs by: Type (Value)
        • 5.2.1.1. Selumetinib
        • 5.2.1.2. Bevacizumab
        • 5.2.1.3. Koselugo
      • 5.2.2. Global Neurofibromatosis Treatment Drugs by: Application (Value)
        • 5.2.2.1. Clinic
        • 5.2.2.2. Hospital
        • 5.2.2.3. Home Care
      • 5.2.3. Global Neurofibromatosis Treatment Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Neurofibromatosis Treatment Drugs by: Neurofibromas (Value)
        • 5.2.4.1. Cutaneous
        • 5.2.4.2. Subcutaneous
        • 5.2.4.3. Plexiform
      • 5.2.5. Global Neurofibromatosis Treatment Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Neurofibromatosis Treatment Drugs (Volume)
      • 5.3.1. Global Neurofibromatosis Treatment Drugs by: Type (Volume)
        • 5.3.1.1. Selumetinib
        • 5.3.1.2. Bevacizumab
        • 5.3.1.3. Koselugo
      • 5.3.2. Global Neurofibromatosis Treatment Drugs by: Application (Volume)
        • 5.3.2.1. Clinic
        • 5.3.2.2. Hospital
        • 5.3.2.3. Home Care
      • 5.3.3. Global Neurofibromatosis Treatment Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Online
        • 5.3.3.2. Offline
      • 5.3.4. Global Neurofibromatosis Treatment Drugs by: Neurofibromas (Volume)
        • 5.3.4.1. Cutaneous
        • 5.3.4.2. Subcutaneous
        • 5.3.4.3. Plexiform
      • 5.3.5. Global Neurofibromatosis Treatment Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Neurofibromatosis Treatment Drugs (Price)
      • 5.4.1. Global Neurofibromatosis Treatment Drugs by: Type (Price)
  • 6. Neurofibromatosis Treatment Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Arno Therapeutics Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Beta Pharma Inc(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lixte Biotechnology Holdings Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Plex Pharmaceuticals Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Recursion Pharmaceuticals Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Genentech (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amgen(United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Allergan(Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Neurofibromatosis Treatment Drugs Sale, by Type, Application, Distribution Channel, Neurofibromas and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Neurofibromatosis Treatment Drugs (Value)
      • 7.2.1. Global Neurofibromatosis Treatment Drugs by: Type (Value)
        • 7.2.1.1. Selumetinib
        • 7.2.1.2. Bevacizumab
        • 7.2.1.3. Koselugo
      • 7.2.2. Global Neurofibromatosis Treatment Drugs by: Application (Value)
        • 7.2.2.1. Clinic
        • 7.2.2.2. Hospital
        • 7.2.2.3. Home Care
      • 7.2.3. Global Neurofibromatosis Treatment Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Neurofibromatosis Treatment Drugs by: Neurofibromas (Value)
        • 7.2.4.1. Cutaneous
        • 7.2.4.2. Subcutaneous
        • 7.2.4.3. Plexiform
      • 7.2.5. Global Neurofibromatosis Treatment Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Neurofibromatosis Treatment Drugs (Volume)
      • 7.3.1. Global Neurofibromatosis Treatment Drugs by: Type (Volume)
        • 7.3.1.1. Selumetinib
        • 7.3.1.2. Bevacizumab
        • 7.3.1.3. Koselugo
      • 7.3.2. Global Neurofibromatosis Treatment Drugs by: Application (Volume)
        • 7.3.2.1. Clinic
        • 7.3.2.2. Hospital
        • 7.3.2.3. Home Care
      • 7.3.3. Global Neurofibromatosis Treatment Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Online
        • 7.3.3.2. Offline
      • 7.3.4. Global Neurofibromatosis Treatment Drugs by: Neurofibromas (Volume)
        • 7.3.4.1. Cutaneous
        • 7.3.4.2. Subcutaneous
        • 7.3.4.3. Plexiform
      • 7.3.5. Global Neurofibromatosis Treatment Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Neurofibromatosis Treatment Drugs (Price)
      • 7.4.1. Global Neurofibromatosis Treatment Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurofibromatosis Treatment Drugs: by Type(USD Million)
  • Table 2. Neurofibromatosis Treatment Drugs Selumetinib , by Region USD Million (2014-2019)
  • Table 3. Neurofibromatosis Treatment Drugs Bevacizumab , by Region USD Million (2014-2019)
  • Table 4. Neurofibromatosis Treatment Drugs Koselugo , by Region USD Million (2014-2019)
  • Table 5. Neurofibromatosis Treatment Drugs: by Application(USD Million)
  • Table 6. Neurofibromatosis Treatment Drugs Clinic , by Region USD Million (2014-2019)
  • Table 7. Neurofibromatosis Treatment Drugs Hospital , by Region USD Million (2014-2019)
  • Table 8. Neurofibromatosis Treatment Drugs Home Care , by Region USD Million (2014-2019)
  • Table 9. Neurofibromatosis Treatment Drugs: by Distribution Channel(USD Million)
  • Table 10. Neurofibromatosis Treatment Drugs Online , by Region USD Million (2014-2019)
  • Table 11. Neurofibromatosis Treatment Drugs Offline , by Region USD Million (2014-2019)
  • Table 12. Neurofibromatosis Treatment Drugs: by Neurofibromas(USD Million)
  • Table 13. Neurofibromatosis Treatment Drugs Cutaneous , by Region USD Million (2014-2019)
  • Table 14. Neurofibromatosis Treatment Drugs Subcutaneous , by Region USD Million (2014-2019)
  • Table 15. Neurofibromatosis Treatment Drugs Plexiform , by Region USD Million (2014-2019)
  • Table 16. South America Neurofibromatosis Treatment Drugs, by Country USD Million (2014-2019)
  • Table 17. South America Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 18. South America Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 19. South America Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 20. South America Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 21. Brazil Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 22. Brazil Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 23. Brazil Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 24. Brazil Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 25. Argentina Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 26. Argentina Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 27. Argentina Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 28. Argentina Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 29. Rest of South America Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 30. Rest of South America Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 31. Rest of South America Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 32. Rest of South America Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 33. Asia Pacific Neurofibromatosis Treatment Drugs, by Country USD Million (2014-2019)
  • Table 34. Asia Pacific Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 35. Asia Pacific Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 36. Asia Pacific Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 37. Asia Pacific Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 38. China Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 39. China Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 40. China Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 41. China Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 42. Japan Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 43. Japan Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 44. Japan Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 45. Japan Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 46. India Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 47. India Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 48. India Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 49. India Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 50. South Korea Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 51. South Korea Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 52. South Korea Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 53. South Korea Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 54. Taiwan Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 55. Taiwan Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 56. Taiwan Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 57. Taiwan Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 58. Australia Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 59. Australia Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 60. Australia Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 61. Australia Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 62. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 66. Europe Neurofibromatosis Treatment Drugs, by Country USD Million (2014-2019)
  • Table 67. Europe Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 68. Europe Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 69. Europe Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 70. Europe Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 71. Germany Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 72. Germany Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 73. Germany Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 74. Germany Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 75. France Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 76. France Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 77. France Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 78. France Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 79. Italy Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 80. Italy Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 81. Italy Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 82. Italy Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 83. United Kingdom Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 84. United Kingdom Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 85. United Kingdom Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 86. United Kingdom Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 87. Netherlands Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 88. Netherlands Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 89. Netherlands Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 90. Netherlands Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 91. Rest of Europe Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 92. Rest of Europe Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 93. Rest of Europe Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 94. Rest of Europe Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 95. MEA Neurofibromatosis Treatment Drugs, by Country USD Million (2014-2019)
  • Table 96. MEA Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 97. MEA Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 98. MEA Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 99. MEA Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 100. Middle East Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 101. Middle East Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 102. Middle East Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 103. Middle East Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 104. Africa Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 105. Africa Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 106. Africa Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 107. Africa Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 108. North America Neurofibromatosis Treatment Drugs, by Country USD Million (2014-2019)
  • Table 109. North America Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 110. North America Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 111. North America Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 112. North America Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 113. United States Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 114. United States Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 115. United States Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 116. United States Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 117. Canada Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 118. Canada Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 119. Canada Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 120. Canada Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 121. Mexico Neurofibromatosis Treatment Drugs, by Type USD Million (2014-2019)
  • Table 122. Mexico Neurofibromatosis Treatment Drugs, by Application USD Million (2014-2019)
  • Table 123. Mexico Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 124. Mexico Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2014-2019)
  • Table 125. Neurofibromatosis Treatment Drugs Sales: by Type(K Tons)
  • Table 126. Neurofibromatosis Treatment Drugs Sales Selumetinib , by Region K Tons (2014-2019)
  • Table 127. Neurofibromatosis Treatment Drugs Sales Bevacizumab , by Region K Tons (2014-2019)
  • Table 128. Neurofibromatosis Treatment Drugs Sales Koselugo , by Region K Tons (2014-2019)
  • Table 129. Neurofibromatosis Treatment Drugs Sales: by Application(K Tons)
  • Table 130. Neurofibromatosis Treatment Drugs Sales Clinic , by Region K Tons (2014-2019)
  • Table 131. Neurofibromatosis Treatment Drugs Sales Hospital , by Region K Tons (2014-2019)
  • Table 132. Neurofibromatosis Treatment Drugs Sales Home Care , by Region K Tons (2014-2019)
  • Table 133. Neurofibromatosis Treatment Drugs Sales: by Distribution Channel(K Tons)
  • Table 134. Neurofibromatosis Treatment Drugs Sales Online , by Region K Tons (2014-2019)
  • Table 135. Neurofibromatosis Treatment Drugs Sales Offline , by Region K Tons (2014-2019)
  • Table 136. Neurofibromatosis Treatment Drugs Sales: by Neurofibromas(K Tons)
  • Table 137. Neurofibromatosis Treatment Drugs Sales Cutaneous , by Region K Tons (2014-2019)
  • Table 138. Neurofibromatosis Treatment Drugs Sales Subcutaneous , by Region K Tons (2014-2019)
  • Table 139. Neurofibromatosis Treatment Drugs Sales Plexiform , by Region K Tons (2014-2019)
  • Table 140. South America Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2014-2019)
  • Table 141. South America Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 142. South America Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 143. South America Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 144. South America Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 145. Brazil Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 146. Brazil Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 147. Brazil Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 148. Brazil Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 149. Argentina Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 150. Argentina Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 151. Argentina Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 152. Argentina Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 153. Rest of South America Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 154. Rest of South America Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 155. Rest of South America Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 156. Rest of South America Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 157. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2014-2019)
  • Table 158. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 159. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 160. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 161. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 162. China Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 163. China Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 164. China Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 165. China Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 166. Japan Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 167. Japan Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 168. Japan Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 169. Japan Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 170. India Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 171. India Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 172. India Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 173. India Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 174. South Korea Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 175. South Korea Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 176. South Korea Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 177. South Korea Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 178. Taiwan Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 179. Taiwan Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 180. Taiwan Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 181. Taiwan Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 182. Australia Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 183. Australia Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 184. Australia Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 185. Australia Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 186. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 187. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 188. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 189. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 190. Europe Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2014-2019)
  • Table 191. Europe Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 192. Europe Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 193. Europe Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 194. Europe Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 195. Germany Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 196. Germany Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 197. Germany Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 198. Germany Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 199. France Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 200. France Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 201. France Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 202. France Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 203. Italy Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 204. Italy Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 205. Italy Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 206. Italy Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 207. United Kingdom Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 208. United Kingdom Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 209. United Kingdom Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 210. United Kingdom Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 211. Netherlands Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 212. Netherlands Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 213. Netherlands Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 214. Netherlands Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 215. Rest of Europe Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 216. Rest of Europe Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 217. Rest of Europe Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 218. Rest of Europe Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 219. MEA Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2014-2019)
  • Table 220. MEA Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 221. MEA Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 222. MEA Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 223. MEA Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 224. Middle East Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 225. Middle East Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 226. Middle East Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 227. Middle East Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 228. Africa Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 229. Africa Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 230. Africa Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 231. Africa Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 232. North America Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2014-2019)
  • Table 233. North America Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 234. North America Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 235. North America Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 236. North America Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 237. United States Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 238. United States Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 239. United States Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 240. United States Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 241. Canada Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 242. Canada Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 243. Canada Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 244. Canada Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 245. Mexico Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2014-2019)
  • Table 246. Mexico Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2014-2019)
  • Table 247. Mexico Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2014-2019)
  • Table 248. Mexico Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2014-2019)
  • Table 249. Neurofibromatosis Treatment Drugs: by Type(USD/Units)
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Neurofibromatosis Treatment Drugs: by Type(USD Million)
  • Table 260. Neurofibromatosis Treatment Drugs Selumetinib , by Region USD Million (2020-2025)
  • Table 261. Neurofibromatosis Treatment Drugs Bevacizumab , by Region USD Million (2020-2025)
  • Table 262. Neurofibromatosis Treatment Drugs Koselugo , by Region USD Million (2020-2025)
  • Table 263. Neurofibromatosis Treatment Drugs: by Application(USD Million)
  • Table 264. Neurofibromatosis Treatment Drugs Clinic , by Region USD Million (2020-2025)
  • Table 265. Neurofibromatosis Treatment Drugs Hospital , by Region USD Million (2020-2025)
  • Table 266. Neurofibromatosis Treatment Drugs Home Care , by Region USD Million (2020-2025)
  • Table 267. Neurofibromatosis Treatment Drugs: by Distribution Channel(USD Million)
  • Table 268. Neurofibromatosis Treatment Drugs Online , by Region USD Million (2020-2025)
  • Table 269. Neurofibromatosis Treatment Drugs Offline , by Region USD Million (2020-2025)
  • Table 270. Neurofibromatosis Treatment Drugs: by Neurofibromas(USD Million)
  • Table 271. Neurofibromatosis Treatment Drugs Cutaneous , by Region USD Million (2020-2025)
  • Table 272. Neurofibromatosis Treatment Drugs Subcutaneous , by Region USD Million (2020-2025)
  • Table 273. Neurofibromatosis Treatment Drugs Plexiform , by Region USD Million (2020-2025)
  • Table 274. South America Neurofibromatosis Treatment Drugs, by Country USD Million (2020-2025)
  • Table 275. South America Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 276. South America Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 277. South America Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 278. South America Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 279. Brazil Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 280. Brazil Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 281. Brazil Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 282. Brazil Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 283. Argentina Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 284. Argentina Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 285. Argentina Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 286. Argentina Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 287. Rest of South America Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 288. Rest of South America Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 289. Rest of South America Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 290. Rest of South America Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 291. Asia Pacific Neurofibromatosis Treatment Drugs, by Country USD Million (2020-2025)
  • Table 292. Asia Pacific Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 293. Asia Pacific Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 294. Asia Pacific Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 295. Asia Pacific Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 296. China Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 297. China Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 298. China Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 299. China Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 300. Japan Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 301. Japan Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 302. Japan Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 303. Japan Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 304. India Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 305. India Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 306. India Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 307. India Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 308. South Korea Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 309. South Korea Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 310. South Korea Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 311. South Korea Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 312. Taiwan Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 313. Taiwan Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 314. Taiwan Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 315. Taiwan Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 316. Australia Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 317. Australia Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 318. Australia Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 319. Australia Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 320. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 321. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 322. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 323. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 324. Europe Neurofibromatosis Treatment Drugs, by Country USD Million (2020-2025)
  • Table 325. Europe Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 326. Europe Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 327. Europe Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 328. Europe Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 329. Germany Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 330. Germany Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 331. Germany Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 332. Germany Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 333. France Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 334. France Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 335. France Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 336. France Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 337. Italy Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 338. Italy Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 339. Italy Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 340. Italy Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 341. United Kingdom Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 342. United Kingdom Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 343. United Kingdom Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 344. United Kingdom Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 345. Netherlands Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 346. Netherlands Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 347. Netherlands Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 348. Netherlands Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 349. Rest of Europe Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 350. Rest of Europe Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 351. Rest of Europe Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 352. Rest of Europe Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 353. MEA Neurofibromatosis Treatment Drugs, by Country USD Million (2020-2025)
  • Table 354. MEA Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 355. MEA Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 356. MEA Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 357. MEA Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 358. Middle East Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 359. Middle East Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 360. Middle East Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 361. Middle East Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 362. Africa Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 363. Africa Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 364. Africa Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 365. Africa Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 366. North America Neurofibromatosis Treatment Drugs, by Country USD Million (2020-2025)
  • Table 367. North America Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 368. North America Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 369. North America Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 370. North America Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 371. United States Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 372. United States Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 373. United States Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 374. United States Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 375. Canada Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 376. Canada Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 377. Canada Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 378. Canada Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 379. Mexico Neurofibromatosis Treatment Drugs, by Type USD Million (2020-2025)
  • Table 380. Mexico Neurofibromatosis Treatment Drugs, by Application USD Million (2020-2025)
  • Table 381. Mexico Neurofibromatosis Treatment Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 382. Mexico Neurofibromatosis Treatment Drugs, by Neurofibromas USD Million (2020-2025)
  • Table 383. Neurofibromatosis Treatment Drugs Sales: by Type(K Tons)
  • Table 384. Neurofibromatosis Treatment Drugs Sales Selumetinib , by Region K Tons (2020-2025)
  • Table 385. Neurofibromatosis Treatment Drugs Sales Bevacizumab , by Region K Tons (2020-2025)
  • Table 386. Neurofibromatosis Treatment Drugs Sales Koselugo , by Region K Tons (2020-2025)
  • Table 387. Neurofibromatosis Treatment Drugs Sales: by Application(K Tons)
  • Table 388. Neurofibromatosis Treatment Drugs Sales Clinic , by Region K Tons (2020-2025)
  • Table 389. Neurofibromatosis Treatment Drugs Sales Hospital , by Region K Tons (2020-2025)
  • Table 390. Neurofibromatosis Treatment Drugs Sales Home Care , by Region K Tons (2020-2025)
  • Table 391. Neurofibromatosis Treatment Drugs Sales: by Distribution Channel(K Tons)
  • Table 392. Neurofibromatosis Treatment Drugs Sales Online , by Region K Tons (2020-2025)
  • Table 393. Neurofibromatosis Treatment Drugs Sales Offline , by Region K Tons (2020-2025)
  • Table 394. Neurofibromatosis Treatment Drugs Sales: by Neurofibromas(K Tons)
  • Table 395. Neurofibromatosis Treatment Drugs Sales Cutaneous , by Region K Tons (2020-2025)
  • Table 396. Neurofibromatosis Treatment Drugs Sales Subcutaneous , by Region K Tons (2020-2025)
  • Table 397. Neurofibromatosis Treatment Drugs Sales Plexiform , by Region K Tons (2020-2025)
  • Table 398. South America Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2020-2025)
  • Table 399. South America Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 400. South America Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 401. South America Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 402. South America Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 403. Brazil Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 404. Brazil Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 405. Brazil Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 406. Brazil Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 407. Argentina Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 408. Argentina Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 409. Argentina Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 410. Argentina Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 411. Rest of South America Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 412. Rest of South America Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 413. Rest of South America Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 414. Rest of South America Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 415. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2020-2025)
  • Table 416. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 417. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 418. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 419. Asia Pacific Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 420. China Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 421. China Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 422. China Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 423. China Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 424. Japan Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 425. Japan Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 426. Japan Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 427. Japan Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 428. India Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 429. India Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 430. India Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 431. India Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 432. South Korea Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 433. South Korea Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 434. South Korea Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 435. South Korea Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 436. Taiwan Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 437. Taiwan Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 438. Taiwan Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 439. Taiwan Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 440. Australia Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 441. Australia Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 442. Australia Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 443. Australia Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 444. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 445. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 446. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 447. Rest of Asia-Pacific Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 448. Europe Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2020-2025)
  • Table 449. Europe Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 450. Europe Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 451. Europe Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 452. Europe Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 453. Germany Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 454. Germany Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 455. Germany Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 456. Germany Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 457. France Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 458. France Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 459. France Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 460. France Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 461. Italy Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 462. Italy Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 463. Italy Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 464. Italy Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 465. United Kingdom Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 466. United Kingdom Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 467. United Kingdom Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 468. United Kingdom Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 469. Netherlands Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 470. Netherlands Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 471. Netherlands Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 472. Netherlands Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 473. Rest of Europe Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 474. Rest of Europe Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 475. Rest of Europe Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 476. Rest of Europe Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 477. MEA Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2020-2025)
  • Table 478. MEA Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 479. MEA Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 480. MEA Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 481. MEA Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 482. Middle East Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 483. Middle East Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 484. Middle East Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 485. Middle East Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 486. Africa Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 487. Africa Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 488. Africa Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 489. Africa Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 490. North America Neurofibromatosis Treatment Drugs Sales, by Country K Tons (2020-2025)
  • Table 491. North America Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 492. North America Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 493. North America Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 494. North America Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 495. United States Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 496. United States Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 497. United States Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 498. United States Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 499. Canada Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 500. Canada Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 501. Canada Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 502. Canada Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 503. Mexico Neurofibromatosis Treatment Drugs Sales, by Type K Tons (2020-2025)
  • Table 504. Mexico Neurofibromatosis Treatment Drugs Sales, by Application K Tons (2020-2025)
  • Table 505. Mexico Neurofibromatosis Treatment Drugs Sales, by Distribution Channel K Tons (2020-2025)
  • Table 506. Mexico Neurofibromatosis Treatment Drugs Sales, by Neurofibromas K Tons (2020-2025)
  • Table 507. Neurofibromatosis Treatment Drugs: by Type(USD/Units)
  • Table 508. Research Programs/Design for This Report
  • Table 509. Key Data Information from Secondary Sources
  • Table 510. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurofibromatosis Treatment Drugs: by Type USD Million (2014-2019)
  • Figure 5. Global Neurofibromatosis Treatment Drugs: by Application USD Million (2014-2019)
  • Figure 6. Global Neurofibromatosis Treatment Drugs: by Distribution Channel USD Million (2014-2019)
  • Figure 7. Global Neurofibromatosis Treatment Drugs: by Neurofibromas USD Million (2014-2019)
  • Figure 8. South America Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 9. Asia Pacific Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 10. Europe Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 11. MEA Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 12. North America Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 13. Global Neurofibromatosis Treatment Drugs: by Type K Tons (2014-2019)
  • Figure 14. Global Neurofibromatosis Treatment Drugs: by Application K Tons (2014-2019)
  • Figure 15. Global Neurofibromatosis Treatment Drugs: by Distribution Channel K Tons (2014-2019)
  • Figure 16. Global Neurofibromatosis Treatment Drugs: by Neurofibromas K Tons (2014-2019)
  • Figure 17. South America Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 18. Asia Pacific Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 19. Europe Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 20. MEA Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 21. North America Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 22. Global Neurofibromatosis Treatment Drugs: by Type USD/Units (2014-2019)
  • Figure 23. Global Neurofibromatosis Treatment Drugs share by Players 2019 (%)
  • Figure 24. Global Neurofibromatosis Treatment Drugs share by Players (Top 3) 2019(%)
  • Figure 25. Global Neurofibromatosis Treatment Drugs share by Players (Top 5) 2019(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Arno Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. Arno Therapeutics Inc (United States) Revenue: by Geography 2019
  • Figure 29. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2019
  • Figure 31. Beta Pharma Inc(United States) Revenue, Net Income and Gross profit
  • Figure 32. Beta Pharma Inc(United States) Revenue: by Geography 2019
  • Figure 33. Lixte Biotechnology Holdings Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Lixte Biotechnology Holdings Inc (United States) Revenue: by Geography 2019
  • Figure 35. Plex Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Plex Pharmaceuticals Inc (United States) Revenue: by Geography 2019
  • Figure 37. Recursion Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. Recursion Pharmaceuticals Inc (United States) Revenue: by Geography 2019
  • Figure 39. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 40. Genentech (United States) Revenue: by Geography 2019
  • Figure 41. Amgen(United States) Revenue, Net Income and Gross profit
  • Figure 42. Amgen(United States) Revenue: by Geography 2019
  • Figure 43. Allergan(Ireland) Revenue, Net Income and Gross profit
  • Figure 44. Allergan(Ireland) Revenue: by Geography 2019
  • Figure 45. Global Neurofibromatosis Treatment Drugs: by Type USD Million (2020-2025)
  • Figure 46. Global Neurofibromatosis Treatment Drugs: by Application USD Million (2020-2025)
  • Figure 47. Global Neurofibromatosis Treatment Drugs: by Distribution Channel USD Million (2020-2025)
  • Figure 48. Global Neurofibromatosis Treatment Drugs: by Neurofibromas USD Million (2020-2025)
  • Figure 49. South America Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 50. Asia Pacific Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 51. Europe Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 52. MEA Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 53. North America Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 54. Global Neurofibromatosis Treatment Drugs: by Type K Tons (2020-2025)
  • Figure 55. Global Neurofibromatosis Treatment Drugs: by Application K Tons (2020-2025)
  • Figure 56. Global Neurofibromatosis Treatment Drugs: by Distribution Channel K Tons (2020-2025)
  • Figure 57. Global Neurofibromatosis Treatment Drugs: by Neurofibromas K Tons (2020-2025)
  • Figure 58. South America Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 59. Asia Pacific Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 60. Europe Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 61. MEA Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 62. North America Neurofibromatosis Treatment Drugs Share (%), by Country
  • Figure 63. Global Neurofibromatosis Treatment Drugs: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Arno Therapeutics Inc (United States)
  • AstraZeneca Plc (United Kingdom)
  • Beta Pharma Inc(United States)
  • Lixte Biotechnology Holdings Inc (United States)
  • Plex Pharmaceuticals Inc (United States)
  • Recursion Pharmaceuticals Inc (United States)
  • Genentech (United States)
  • Amgen(United States)
  • Allergan(Ireland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation